Oncotarget

Research Papers:

Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer

Weili Duan, Lutao Du, Xiumei Jiang, Rui Wang, Suzhen Yan, Yujiao Xie, Keqiang Yan, Qingliang Wang, Lili Wang, Xin Zhang, Hongwei Pan, Yongmei Yang and Chuanxin Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:78850-78858. https://doi.org/10.18632/oncotarget.12880

Metrics: PDF 1505 views  |   HTML 1365 views  |   ?  


Abstract

Weili Duan1,*, Lutao Du1,*, Xiumei Jiang1, Rui Wang1, Suzhen Yan1, Yujiao Xie1, Keqiang Yan2, Qingliang Wang3, Lili Wang1, Xin Zhang1, Hongwei Pan1, Yongmei Yang1, Chuanxin Wang1

1Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China

2Department of Urology, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China

3Department of Medical Affairs Management, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China

*These authors contributed equally to this work

Correspondence to:

Chuanxin Wang, email: cxwang@sdu.edu.cn

Keywords: lncRNA, bladder cancer, diagnosis, recurrence, serum

Received: July 25, 2016     Accepted: October 14, 2016     Published: October 25, 2016

ABSTRACT

Accumulating evidence indicates that long non-coding RNAs (lncRNAs) play important roles in tumorigenesis and progression. We aimed to identify a panel of lncRNAs for the diagnosis and recurrence prediction in bladder cancer (BC). The expression of 13 candidate lncRNAs was investigated in 80 BC and matched adjacent normal tissues via quantitative real-time PCR. The differentially expressed lncRNAs were then analyzed in 240 serum samples (training set) and three lncRNAs (MEG3, SNHG16 and MALAT1) showed differential expression. A logistic regression model was constructed using the training set and validated in an independent cohort of 200 serum samples (validation set). The AUC of the three-lncRNA panel was 0.865 for the training and 0.828 for the validation set. The diagnostic performance of the lncRNA panel for Ta, T1, and T2–T4 were 0.778, 0.805, and 0.880, which were significantly higher than those of urine cytology (0.548, 0.604, and 0.682, respectively). Moreover, we determined that low expression of MEG3 was associated with poor recurrence-free survival by Kaplan-Meier analysis (p = 0.028), univariate Cox analysis (p = 0.033) and multivariate Cox analysis (p = 0.046). In conclusion, our results identified a three-lncRNA panel for BC diagnosis and a recurrence-independent prognostic factor, MEG3.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12880